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ARTICLE
Epidemiological and clinical factors impact on 
the benefit of riluzole in the survival rates of 
patients with ALS
Impacto de fatores epidemiológicos e clínicos sobre o benefício do riluzol nas taxas de 
sobrevida de pacientes com ELA
Francis Meire Fávero1, Mariana Callil Voos2, Isac de Castro3, Fátima Aparecida Caromano2, Acary Souza 
Bulle Oliveira1
Amyotrophic lateral sclerosis (ALS) results from the 
degeneration of upper and lower motor neurons1. The life 
expectancy of a person with ALS averages two to five years 
from the time of diagnosis. However, large variability is 
observed, according to the initial symptoms2. A higher inci-
dence of ALS among men is noted1,2,3,4,5 and can be explained 
by a higher proportion of men exposed to toxins at work1,3,6,7.
The ALS diagnosis is related to the history and pro-
gression of the disease. It may be difficult to diagnose early 
because it may mimic several other neurological diseases. 
Tests to rule out other conditions may include electromy-
ography, nerve conduction studies, magnetic resonance 
imaging (MRI), blood and urine tests, lumbar puncture 
and muscle biopsy. The diagnoses requires: 1) the pres-
ence of signs of lower motor neuron degeneration in clini-
cal, electrophysiological or neuropathologic examination; 
2) signs of upper motor neuron degeneration in the clini-
cal examination, and 3) progressive spread of signs within 
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ABSTRACT
Objective: To investigate the impact of epidemiological and clinical factors on the benefit of riluzole in patients with amyotrophic lateral 
sclerosis (ALS). Methods: The survival rate of 578 patients with ALS (1999-2011) was analyzed by descriptive statistics and Kaplan-Meier 
curves. Considering the median of the sample survival time (19 months), patients were divided in two groups: below (B19) and above the 
median (A19). Kaplan-Meier curves compared the survival rates of patients treated with riluzole and with patients who did not take the 
medication. Results: Riluzole increased the survival rates of patients with lower limb onset who were diagnosed after the first appointment 
in B19. Patients with bulbar onset and diagnosed on the first, or after the first appointment showed higher survival rates in A19. Males lived 
longer than females in both groups. Conclusion: Epidemiological and clinical factors influenced the benefit of riluzole in the survival rates 
of patients with ALS.
Keywords: epidemiology; amyotrophic lateral sclerosis; motor neuron disease; survival; riluzole
RESUMO
Objetivo: Investigar o impacto de fatores epidemiológicos e clínicos sobre o benefício do riluzole em pacientes com esclerose lateral 
amiotrófica (ELA). Métodos: A sobrevida de 578 pacientes com ELA (1999-2011) foi analisada por estatística descritiva e curvas de 
Kaplan-Meier. Considerando a mediana do tempo de sobrevida (19 meses), a amostra foi subdividida em dois grupos: sobrevida abaixo (B19) 
e acima de 19 meses (A19). As curvas de Kaplan-Meier compararam a sobrevida de pacientes tratados com riluzole e com pacientes que 
não receberam tratamento. Resultados: O riluzole aumentou a sobrevida de pacientes com início nos membros inferiores e diagnosticados 
após a primeira consulta no grupo B19. Pacientes com início bulbar e diagnosticados na primeira/ após a primeira consulta  apresentaram 
maior sobrevida em A19. Os homens apresentaram sobrevida maior do que as mulheres. Conclusão: Foram encontradas diferenças 
epidemiológicas e clínicas no benefício do riluzole em pacientes com ELA.
Palavras-chave: epidemiologia; esclerose amiotrófica lateral; doença dos neurônios motores; sobrevivência; riluzole.
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a region or to other regions, together with the absence 
of electrophysiological evidence of other processes that 
might explain the degeneration; and neuroimaging evi-
dence of other processes that might explain the clinical 
and electrophysiological signs8.
The time interval between the first symptoms and 
the diagnosis influences the ALS prognosis9. In the early 
stages, symptoms may go unrecognized and undiagnosed. 
Muscles may be weak or spastic and cramping and fascic-
ulations may occur, as atrophy progresses. Symptoms are 
usually limited to a single body region or mild symptoms 
may affect more than one region. The patient may experi-
ence fatigue, gait instability, changes in speed or rhythm 
during speech, and a weak hand grip. Survival time after 
diagnosis is variable in the literature ( from eight to 
66 months)5,6,7,9,10,11,12,13,14,15,16,17,18,19,20,21,22. In general, shorter 
intervals from symptom onset to diagnosis predict lower 
survival rates. 
Riluzole is the only treatment that increases the survival 
rate of patients with ALS. Models in vitro, after excitotoxic 
action in motor neurons, showed the regression of lesions and 
the reduction of glutamatergic spontaneous events. Patients 
with bulbar onset benefited more from riluzole administra-
tion than patients with limb onset9,15. However, lower limb 
onset is usually associated with higher survival rates than 
the upper limb onset and bulbar forms7,15. The use of nonin-
vasive ventilation improves the prognosis of ALS patients, 
because it compensates for respiratory muscle weakness23. 
Gastrostomy feeding provides long-term nutritional support 
for patients with dysphagia23.
The present study aimed to investigate the effect of 
riluzole on the survival rates of patients with ALS in one 
Brazilian center, considering epidemiological (age, gender 
and race) and clinical aspects (initial symptoms topogra-
phy, time from first symptoms to neurologic evaluation, 
time from first symptoms to electromyography, time from 
first symptoms to diagnosis).
Considering the epidemiological factors, we believed 
that older patients and males would show lower survival 
rates and that a higher incidence would be found among 
whites. Considering the clinical aspects, we hypothesized 
that patients showing lower limb initial symptom topogra-
phy would show higher survival rates. In these cases, the 
time to progression of weakness or spreading would be lon-
ger than in patients with upper limb, or bulbar, onset. We 
also hypothesized that patients with a longer time interval 
from first symptoms to neurologic evaluation, electromyog-
raphy and/or diagnosis would show higher survival rates. 
In these cases, we supposed that early stage ALS would last 
longer, with slower progression and, consequently, a higher 
survival rate. We hypothesized that patients treated with 
riluzole would show higher survival rates than patients who 
did not take the medication.
METHODS
This was a prospective cohort study. It was approved by the 
Ethics Committee of Federal University of São Paulo. During 
the 12-year study period ( from 1999-2011), we identified 
patients in the Motor Neuron Disease Clinic from the Clinical 
Investigation on Neuromuscular Diseases Section, Department 
of Neurology and Neurosurgery of the Federal University of São 
Paulo. These patients received an ALS diagnosis, according 
to the El Escorial of World Federation of Neurology Research 
Group on Neuromuscular Diseases criteria8.
We collected epidemiological, clinical and therapeutic data 
from charts. Epidemiological variables consisted of age, gender 
and race. Clinical data included initial symptoms topography, 
time from first symptoms to neurologic evaluation, time from 
first symptoms to diagnosis (before, at or after the first appoint-
ment with the neurologist), the moment when electroneuro-
myography was solicited (at or after the first appointment) and 
the survival rate ( from diagnosis to death). Therapeutic data 
were registered if riluzole and non-invasive ventilation were pre-
scribed or not. All patients received interdisciplinary treatment 
(neurologist, occupational therapist, motor and respiratory 
physical therapist, psychologist, nutritionist and social assistant) 
and differed only in whether the patient received riluzole or not.
Statistical analysis
Continuous and semicontinuous data were initially com-
pared in a Gauss curve with the Kolmogorov-Smirnov test. 
Non-parametrical data were represented by the median 
and percentiles and compared by Mann-Whitney tests. 
Categorical data were represented by absolute (n) and rela-
tive (%) frequencies and analyzed by Chi-square tests. The 
survival rate was analyzed by Kaplan-Meier curves and rep-
resented by medians of survival estimations and standard 
errors of estimations. Comparisons between survival curves 
were made using the log-rank test. All comparisons consid-
ered the alpha risk below 5% as type I error and below 20% as 
type II error. The SPSS 19.0 was used in all analyses.
RESULTS
Charts from 1,146 patients with motor neuron diseases 
were analyzed. Of the 578 charts meeting the El Escorial 
diagnosis criteria for ALS, 231 had the date of death available. 
These 231 patients were included and the impact of epidemi-
ological and clinical characteristics on the benefit of riluzole 
on the survival rate was investigated.
Kaplan-Meier curves are based on life expectancy. The 
median of survival time was 19 months. The survival curves 
included 144 patients who survived from one to 19 months 
after ALS diagnosis (survival time below 19 months: B19) and 
87 patients who survived longer than 19 months after ALS 
diagnosis (survival time above 19 months: A19) (Figure 1).
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Epidemiological characteristics
Considering the total sample, 56.1% were males (n = 131), 
with the ratio male: female of 1.32:1 (p = 0.001). Ethnicity was 
90% Caucasian (n = 209), 9% African (n = 19) and 1% Asian 
(n = 3). All cases were sporadic. The medians of age were 63 
years in B19 and 57 years in A19 (p < 0.050).
Clinical characteristics
The moment of the diagnosis influenced the sur-
vival rate. In the A19 group, patients diagnosed after 
the first appointment with the neurologist lived longer 
(21.1 months, p = 0.029), compared to the ones diagnosed 
before the first appointment with the neurologist, by a 
physician with another specialty (17.4 months, p = 0.157), 
and compared to the ones diagnosed on the first appoint-
ment (13.7 months, p = 0.361).
Considering the electromyography, seven patients were 
not submitted to the exam before the first appointment with 
the neurologist. These patients lived longer (18.4 months) 
than the ones submitted to the exam before the first appoint-
ment (15.9 months).
The Table shows the medians of the time from the first 
symptoms to the diagnosis and total survival time ( from early 
symptoms to death), followed by a comparison with other 
studies. The time between the first symptoms and the first 
appointment varied from nine to 26 months, with a median 
of 16 months, considering the whole group, 15 months in the 
B19 group and 13 months in the A19 group. 
Riluzole treatment
In the B19 group (n = 144), 82 patients (56.9%) were 
treated with riluzole and in the A19 group (n = 87), 53 patients 
(60.9%) received the drug. Riluzole influenced the survival 
rate of the A19 group, but not of the B19 group. In the B19 
group, the median survival of patients receiving riluzole was 
4.5 months. The median survival time of patients who did 
not receive the drug was 3.4 months (p = 0.176) (Figure 2A). 
Patients treated with riluzole lived longer than the patients 
who were not treated with this drug (18.3 versus 13.7 months, 
p = 0.001) (Figure 2B). 
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Figure 1. Survival time.
Table. Time intervals (median, in months) between the first symptoms and the diagnosis, and between the diagnosis and death. 
Authors Year First symptoms to diagnosis Range
Diagnosis to death 
(survival) Range
Dietrich-Neto10 2000 11 0 - 332 42 7 - 191
Tomik11 2000 NM NM 38 10 - 218
Aguila9 2003 32 NM 19 NM
Traynor12 2003 10 1 - 110 NM NM
Forbes13 2004 15 Jun-17 28 17 - 50
Mandrioli7 2006 9 NM 29 NM
Beghi14 2006 39 NM 30 NM
Zoccolella15 2007 8 Jan-70 18 Jan-48
Logroscino5 2008 19 16 - 31 30 27 - 39
Logroscino16 2010 9 May-14 NM NM
Turner17 2010a 15 2 - 216 41 33 - 49
Turner18 2010b 9 Feb-34 27 20 - 34
Fujimura-Kiyono19 2011 14 NM 32 Mar-60
Chió20 2011a 9 May-14 NM NM
Chió21 2011b NM NM 46 40 - 53
Roche22 2012 NM NM 42 NM
Lee6 2013 NM NM 66 59 - 82
Favero et al. (this article) 2013 14 Oct-24 19 Sep-41
NM: not mentioned.
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We found a difference between males, but not between 
females when we compared the effect of riluzole. In the A19 
group, males treated with riluzole showed a higher survival 
rate (19.9 months) than the ones who were not medicated 
(14.2 months, p = 0.004). The diagnosis before (Figure 3A, D), 
at (Figure 3B, E) or after (Figure 3C, F) the first appoint-
ment with the neurologist and the response to riluzole dif-
fered in the B19 and A19 groups. In the A19 group, patients 
who received the prescription of riluzole at the first appoint-
ment showed longer survival times (15.0 months) compared 
with those who were not treated with this drug (9.6 months, 
p < 0.001) (Figure 3E).
The topography of the first symptoms (upper limbs, 
lower limbs and bulbar onset) and the response to rilu-
zole differed in the B19 (Figure 4A, B and C) and A19 
groups (Figure 4D, E and F). In the B19 group, patients 
treated with riluzole showed longer survival times (5.3 
months), compared with patients who did not take the 
medication (2.6 months, p = 0.010) (Figure 4C). In the 
A19 group, patients with bulbar onset treated with rilu-
zole showed shorter survival times (18.3 months) than 
the ones who did not receive the medication (9.5 months, 
p < 0.001) (Figure 4D).
Riluzole and non-invasive ventilation prescriptions
In the B19 group (n = 144), 62 patients did not receive a 
riluzole prescription (12 without noninvasive ventilation and 
50 with noninvasive ventilation) and 82 patients were treated 
with riluzole (eight without noninvasive ventilation and 74 
with noninvasive ventilation). The chi-square test showed 
that there was no difference in the number of patients with 
noninvasive ventilation in the subgroups with or without 
riluzole prescription (p = 0.101).
In the A19 group (n = 87), 34 patients did not receive the 
prescription of riluzole (two without noninvasive ventilation 
and 32 with noninvasive ventilation) and 53 patients were 
treated with riluzole (six without noninvasive ventilation and 
47 with noninvasive ventilation). The chi-square test showed 
that there was no difference in the number of patients with 
noninvasive ventilation in the subgroups with or without 
riluzole prescription (p = 0.391).
DISCUSSION
The present study investigated epidemiological and 
clinical factors that could be influenced by the treatment 
with riluzole. The survival rate depends not only on the 
treatment with riluzole, but also on populational char-
acteristics and studies inclusion/exclusion criteria21,23.  
Many factors may interfere with the ALS prognosis and 
interact with the effect of riluzole, e.g. nonspecific symp-
toms in early stages, the type of clinical impairment, time 
between the first symptoms and the first appointment with 
a neurologist, and the time before the start of treatment 
(medication/rehabilitation).
A high number of patients died before 19 months. 
Considering the follow-up time ( from the first symptoms to 
death) and the survival time ( from the diagnosis to death), 
differences favoring the A19 group were found: patients diag-
nosed in the early stages and patients presenting with their 
first symptoms in their lower limbs survived longer.
Figure 2. Survival time of ALS patients who did, or did not, receive riluzole.
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Many patients showed severe clinical impairment in the 
first clinical evaluation. This means that there was a long 
interval between the first symptoms and the first appoint-
ment ( from 10 to 24 months, median: 14 months). The late 
diagnosis and the more severe impairments shown on the 
first neurological assessment may have contributed to a 
shorter survival time. Clinical studies showed that survival 
time is shorter in more impaired patients4,15.
Many studies showed that patients with ALS treated with 
riluzole (50 mg/twice a day) survive longer6,15,23. Lee et al.6 
showed that the mortality rate among patients receiving 
riluzole was reduced by almost 66%. However, patients 
who started treatment with severe and generalized clinical 
impairment had less benefit from riluzole. The glutamater-
gic action of riluzole depends on viable motor neuron activ-
ity. Therefore, if a high number of neurons is damaged, the 
riluzole does not show significant effects24. Bensimon et al.25 
showed that the survival rate after 12 months was signifi-
cantly higher for patients receiving riluzole, compared to 
those receiving placebo. Miller et al.23 reported that riluzole 
may have beneficial effects on bulbar and limb functions, but 
not on muscle strength.
Epidemiological characteristics
In the present study, the median age of the B19 group 
was 63 and of the A19 group was 57 years old (p < 0.050). 
The study by Palermo et al.2 found a lower mean age in a 
Brazilian sample (52 years of age). A retrospective study with 
1,226 patients with ALS showed a median survival time of 25 
months (range: 16–34 months) and described an age differ-
ence, benefiting younger patients on clinical presentation, 
survival rate and functional independence13. Mandrioli et al.7, 
Zoccolella et al.15 and Lee et al.6 also associated a greater age 
with a lower survival rate. Zoccolella et al.15 mentioned that 
Figure 3. Moment of diagnosis.
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older patients, although showing lower survival rates, had 
more benefits from riluzole.
The survival rate differed between men and women. 
Matos et al.26 compared the mortality of men and women: 
158 men versus 168 women with ALS, which resulted in no 
significant gender differences. Mandrioli et al.7 mentioned no 
gender influence on survival rate. On the contrary, the pres-
ent study found 127 men (55%) and 104 women (45%) with 
ALS. This predominance of males agrees with the studies 
by Lee et al.6, McCombe and Henderson3, Zoccolella et al.15, 
Argyriou et al.1, Palermo et al.2 and Logroscino et al.4,5,16. Some 
studies reported that this male preponderance is due to heavy 
industries and agricultural jobs1,3,6,7. However, some authors 
did not find this difference. Matos et al.26 and Werneck et al.27 
compared the incidence of ALS among men and women. They 
analyzed death certificates and hospital charts from two dif-
ferent regions of Brazil and found no gender differences. 
The influence of gender on survival rate is controver-
sial in the literature. McCombe and Henderson3 stated that 
gender did not show a clear effect on survival. The study by 
Lee et al.6 showed lower survival rates in men, compared 
to women. This could be explained by a toxic effect of a 
mutant SOD1 protein in the cerebrospinal fluid in men28. 
Norris et al.29 stated that gender differences diminished 
with increasing age. In contrast, Aguila et al.9 found that an 
older age and female gender were strongly associated with 
lower survival rates, and Norris et al.29 reported that women 
may show the first symptoms of ALS later in life than men, 
but men may experience longer courses with milder paraly-
sis than women.
Figure 4. Topography.
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Nygren et al.30 described that women were less frequently 
treated with riluzole than men. The lower frequency of prescrip-
tion of riluzole among women may have influenced the survival 
rates of women and men in studies by both Aguila et al.9 and 
Nygren et al.30. Another possible explanation is that men can take 
longer than women to see a neurologist, and show more typical 
symptoms in the first visit due to ALS progression. On the other 
hand, women may visit the physician too early, with nonspecific 
symptoms, which results in a longer time interval before diagnosis.
The effects of symptoms topography and riluzole 
on survival rates
We observed a positive effect of riluzole in the B19 group, 
in patients with lower limb onset. These patients may have 
survived longer because this topography has a less aggressive 
time course, with a bottom-up evolution. Zoccolella et al.15 
and Mandrioli et al.7 observed that lower limb onset was 
associated with longer survival than upper limb and bulbar 
onsets. Lower limb onset shows a longer progression and 
higher survival rates because the motor neurons that are 
close to the ones degenerating are affected. Therefore, the 
propagation of clinical manifestations occurs contiguously, 
and it takes longer to impair spinal and bulbar structures 
related to vital functions (breathing, swallowing)17,20.
The bulbar phenotype seems to interact with age. 
According to Norris et al.29, the risk of a bulbar onset and 
lower survival rate increases with age. Turner et al.18, con-
versely, described survival rates in bulbar onset ALS as highly 
variable, and Chiò et al.21 stated that age at onset is higher in 
the bulbar phenotype.
In the A19 group, riluzole benefited patients with bul-
bar onset. As bulbar manifestations are usually the most 
evident, although diagnostic confirmation may be more 
difficult, the search for a physician may have occurred 
earlier. This may have favored an earlier therapeutic 
intervention, justifying a better response in the group 
treated with riluzole. Zoccolella et al.15 verified a more 
evident effect of riluzole in bulbar onset ALS patients 
than in limb onset patients.
Not only riluzole, but also therapies to provide a bet-
ter physical and respiratory condition, may also have con-
tributed to a longer survival of the A19 group. Noninvasive 
ventilation treats respiratory insufficiency and percutane-
ous endoscopic gastrostomy can stabilize weight. These 
actions prolong survival in patients with ALS23. Czell et 
al.31 verified that the association of noninvasive ventila-
tion and percutaneous endoscopic gastrostomy in ALS 
patients with moderate to severe impaired ventilation may 
have beneficial outcomes, even in ALS patients with severe 
respiratory impairment.
The effects of the time of diagnosis and riluzole on 
survival rates
In the B19 and A19 groups, patients diagnosed after the 
first appointment benefited from riluzole. In the A19 group, 
patients diagnosed at the first appointment also showed a 
significant positive effect of riluzole on survival time. These 
patients may have had longer early stage times, less general-
ized clinical impairment and, consequently, slower ALS pro-
gression. Therefore, they took longer to seek medical assis-
tance. However, more severe patients benefited from early 
diagnosis and treatment. Ludolph and Jesse24 stated that 
the early diagnosis may have been the major reason for the 
change in the ALS prognosis.
Seven patients were not assessed with electromyography 
before the first appointment with the neurologist and sur-
vived longer than those with electromyography results com-
patible or not compatible with ALS. We believe that patients 
without a defined diagnosis after the appointment with the 
neurologist were probably less affected clinically. The diagno-
sis at that moment was not possible, and a longer time was 
needed to define and confirm the diagnosis. Besides, in the 
public health system in Brazil, the early diagnosis of ALS may 
be challenging due to socioeconomic problems and this may 
negatively influence clinical outcomes. Therefore, the median 
of the total survival time was lower than in other studies.
As a limitation of this study, we must mention that informa-
tion about sleep studies and gastrostomy was not available and 
may have influenced the survival rates. Future studies should 
investigate the influence of these variables in ALS survival.   
In conclusion, gender, first symptoms topography and the 
moment of diagnosis affected the prognosis of patients with 
ALS. The benefits of riluzole were influenced by epidemio-
logical and clinical factors.
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Erratum
Epidemiological and clinical factors impact on the benefit of riluzole in the survival rates of patients with ALS
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The columns RANGE of the table:
Table. Time intervals (median, in months) between the first symptoms and the diagnosis, and between the diagnosis and death. 
Authors Year First symptoms to diagnosis Range Diagnosis to death (survival) Range
Dietrich-Neto10 2000 11 0 - 332 42 7 - 191
Tomik11 2000 NM NM 38 10 - 218
Aguila9 2003 32 NM 19 NM
Traynor12 2003 10 1 - 110 NM NM
Forbes13 2004 15 Jun-17 28 17 - 50
Mandrioli7 2006 9 NM 29 NM
Beghi14 2006 39 NM 30 NM
Zoccolella15 2007 8 Jan-70 18 Jan-48
Logroscino5 2008 19 16 - 31 30 27 - 39
Logroscino16 2010 9 May-14 NM NM
Turner17 2010a 15 2 - 216 41 33 - 49
Turner18 2010b 9 Feb-34 27 20 - 34
Fujimura-Kiyono19 2011 14 NM 32 Mar-60
Chió20 2011a 9 May-14 NM NM
Chió21 2011b NM NM 46 40 - 53
Roche22 2012 NM NM 42 NM
Lee6 2013 NM NM 66 59 - 82
Favero et al. (this article) 2013 14 Oct-24 19 Sep-41
NM: not mentioned.
Table. Time intervals (median, in months) between the first symptoms and the diagnosis and between the diagnosis and death.
Authors Year First symptoms to diagnosis Range Diagnosis to death (survival) Range
Dietrich-Neto10 2000 11 0 - 332 42 7 - 191
Tomik11 2000 NM NM 38 10 - 218
Aguila9 2003 32 NM 19 NM
Traynor12 2003 10 1 - 110 NM NM
Forbes13 2004 15 6 - 17 28 17 - 50
Mandrioli7 2006 9 NM 29 NM
Beghi14 2006 39 NM 30 NM
Zoccolella15 2007 8 1 - 70 18 1 - 48
Logroscino5 2008 19 16 - 31 30 27 - 39
Logroscino16 2010 9 5 - 14 NM NM
Turner17 2010a 15 2 - 216 41 33 - 49
Turner18 2010b 9 2 - 34 27 20 - 34
Fujimura-Kiyono19 2011 14 NM 32 3 - 60
Chió20 2011a 9 5 - 14 NM NM
Chió21 2011b NM NM 46 40 - 53
Roche22 2012 NM NM 42 NM
Lee6 2013 NM NM 66 59 - 82
Favero 2013 14 10 - 24 19 9 - 41
NM: not mentioned.
Should be:
